BSE Live
Sep 25, 16:01Prev. Close
1076.25
Open Price
1075.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 25, 15:49Prev. Close
1080.30
Open Price
1066.10
Bid Price (Qty.)
1071.40 (4)
Offer Price (Qty.)
0.00 (0)
Key Financial Ratios of Jubilant Pharmova (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
Per Share Ratios | ||||||
Basic EPS (Rs.) | 1.21 | 1.99 | 3.13 | 4.93 | 13.47 | |
Diluted EPS (Rs.) | 1.21 | 1.99 | 3.13 | 4.93 | 13.47 | |
Cash EPS (Rs.) | 4.55 | 5.03 | 5.85 | 5.32 | 19.74 | |
Book Value [ExclRevalReserve]/Share (Rs.) | 145.79 | 149.34 | 151.57 | 80.47 | 80.51 | |
Book Value [InclRevalReserve]/Share (Rs.) | 145.79 | 149.34 | 151.57 | 80.47 | 80.51 | |
Dividend / Share(Rs.) | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | |
Revenue from Operations/Share (Rs.) | 46.90 | 49.35 | 50.85 | 5.51 | 170.09 | |
PBDIT/Share (Rs.) | 8.28 | 7.54 | 8.86 | 7.48 | 29.81 | |
PBIT/Share (Rs.) | 4.94 | 4.50 | 6.14 | 7.08 | 23.54 | |
PBT/Share (Rs.) | 2.36 | 2.62 | 4.98 | 5.16 | 17.15 | |
Net Profit/Share (Rs.) | 1.21 | 1.99 | 3.13 | 4.93 | 13.46 | |
Profitability Ratios | ||||||
PBDIT Margin (%) | 17.66 | 15.27 | 17.41 | 135.70 | 17.52 | |
PBIT Margin (%) | 10.54 | 9.12 | 12.08 | 128.58 | 13.83 | |
PBT Margin (%) | 5.04 | 5.31 | 9.79 | 93.73 | 10.08 | |
Net Profit Margin (%) | 2.57 | 4.02 | 6.15 | 89.46 | 7.91 | |
Return on Networth / Equity (%) | 0.82 | 1.33 | 2.06 | 6.12 | 16.72 | |
Return on Capital Employed (%) | 3.02 | 2.67 | 3.69 | 6.29 | 21.74 | |
Return on Assets (%) | 0.65 | 1.05 | 1.65 | 4.29 | 11.62 | |
Total Debt/Equity (X) | 0.13 | 0.14 | 0.12 | 0.39 | 0.38 | |
Asset Turnover Ratio (%) | 0.25 | 0.26 | 0.33 | 0.05 | 146.88 | |
Liquidity Ratios | ||||||
Current Ratio (X) | 1.56 | 1.71 | 1.60 | 1.27 | 0.55 | |
Quick Ratio (X) | 0.81 | 0.92 | 0.73 | 1.27 | 0.55 | |
Inventory Turnover Ratio (X) | 3.09 | 1.10 | 0.00 | 0.00 | 0.00 | |
Dividend Payout Ratio (NP) (%) | 414.58 | 251.89 | 159.65 | 101.44 | 0.00 | |
Dividend Payout Ratio (CP) (%) | 110.09 | 99.62 | 85.51 | 93.96 | 0.00 | |
Earnings Retention Ratio (%) | -314.58 | -151.89 | -59.65 | -1.44 | 0.00 | |
Cash Earnings Retention Ratio (%) | -10.09 | 0.38 | 14.49 | 6.04 | 0.00 | |
Valuation Ratios | ||||||
Enterprise Value (Cr.) | 14,487.43 | 9,345.95 | 4,735.77 | 6,654.15 | 11,291.45 | |
EV/Net Operating Revenue (X) | 19.43 | 11.91 | 5.85 | 75.83 | 4.17 | |
EV/EBITDA (X) | 110.00 | 77.95 | 33.56 | 55.88 | 23.77 | |
MarketCap/Net Operating Revenue (X) | 19.03 | 11.52 | 5.49 | 70.40 | 4.00 | |
Retention Ratios (%) | -314.58 | -151.89 | -59.65 | -1.44 | 0.00 | |
Price/BV (X) | 6.12 | 3.81 | 1.84 | 4.82 | 8.45 | |
Price/Net Operating Revenue | 19.03 | 11.52 | 5.49 | 70.40 | 4.00 | |
Earnings Yield | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
20.07.2025
16.06.2025
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
16.05.2025
Jubilant Pharmo Consolidated March 2025 Net Sales at Rs 1,928.80 crore, up 9.68% Y-o-Y
16.05.2025
Jubilant Pharmo Standalone March 2025 Net Sales at Rs 217.30 crore, up 5.59% Y-o-Y
18.01.2021
Jubilant Life Sciences Q3 PAT seen up 14.9% YoY to Rs. 238 cr: Prabhudas Lilladher
12.07.2019
Jubilant Life Sciences Q1 PAT may dip 10.4% YoY to Rs. 181.4 cr: Prabhudas Lilladher
12.04.2019
Jubilant Life Sciences Q4 PAT seen up 36.3% YoY to Rs. 211.2 cr: Prabhudas Lilladher
11.01.2019
Jubilant Life Science Q3 PAT seen up 13.8% YoY to Rs. 241.8 cr: ICICI Direct